Equity Overview
Price & Market Data
Price: $2.98
Daily Change: $0.00 / 0.00%
Daily Range: $0 - $0
Market Cap: $19,499,678
Daily Volume: 0
Performance Metrics
1 Week: -33.63%
1 Month: -56.24%
3 Months: 31.86%
6 Months: -69.72%
1 Year: -73.64%
YTD: 59.36%
Company Details
Employees: 20
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
BiomX Inc., a clinical-stage biopharmaceutical company, develops phage-based therapies using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company's phage-based therapies include fixed cocktail therapy, which involves developing a single product containing a fixed number of selected phages to cover a range of bacterial strains; and personalized therapy, which involves developing a large library of phages from which single optimal phages are personally matched to treat specific patients. It develops BX011, a fixed multi-phage cocktail, which is in Phase 2a trial for the treatment of diabetic foot infections; and BX211, a phage therapy, which is in Phase 2 trial for the treatment of diabetic foot osteomyelitis. BiomX Inc. was founded in 2015 and is based in Dover, Delaware.